{"transactions":[{"id":388382,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY","position":2,"cik":"0000014272","reported_name":"BRISTOL MYERS SQUIBB CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Option Warrant","published_at":"2020-07-13T22:27:21.000Z","date":"2020-07-09","kind":"other","acquired":false,"shares":38979,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable."}],"balance_after":0,"derivative":{"exercise_price":5.88,"expiration_date":"2020-07-09","underlying":"Common Stock, $0.001 par value","underlying_shares":38979},"source":{"system":"sec-edgar","filing":"0001104659-20-083172","document":"tm2024764-1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/14272/000110465920083172/tm2024764-1_4.xml","form_type":"4"}},{"id":388381,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY","position":2,"cik":"0000014272","reported_name":"BRISTOL MYERS SQUIBB CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-13T22:27:21.000Z","date":"2020-07-09","kind":"sale","acquired":false,"shares":2241,"price":102.28,"value":229209.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On July 9, 2020, the Reporting Persons exercised a warrant to purchase 38,979 shares of the Issuer's common stock for $5.88 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Issuer withholding 2,241 of the warrant shares to pay the exercise price and issuing to the Reporting Persons the remaining 36,738 shares."}],"balance_after":7008510,"source":{"system":"sec-edgar","filing":"0001104659-20-083172","document":"tm2024764-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/14272/000110465920083172/tm2024764-1_4.xml","form_type":"4"}},{"id":388380,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY","position":2,"cik":"0000014272","reported_name":"BRISTOL MYERS SQUIBB CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-13T22:27:21.000Z","date":"2020-07-09","kind":"other","acquired":true,"shares":38979,"price":5.88,"value":229196.52,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"This statement is being filed jointly by Celgene Corporation and Bristol-Myers Squibb Company (the \"Reporting Persons\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Celgene Corporation, which is a wholly owned subsidiary of Bristol-Myers Squibb Company. Bristol-Myers Squibb Company is an indirect beneficial owner of the reported securities."}],"balance_after":7010751,"source":{"system":"sec-edgar","filing":"0001104659-20-083172","document":"tm2024764-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/14272/000110465920083172/tm2024764-1_4.xml","form_type":"4"}},{"id":388593,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY","position":2,"cik":"0000014272","reported_name":"BRISTOL MYERS SQUIBB CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-06T21:24:22.000Z","date":"2020-07-01","kind":"purchase","acquired":true,"shares":108108,"price":92.5,"value":9999990.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"This statement is being filed jointly by Celgene Corporation and Bristol-Myers Squibb Company."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Celgene Corporation, which is a wholly owned subsidiary of Bristol-Myers Squibb Company. Bristol-Myers Squibb Company is an indirect beneficial owner of the reported securities."}],"balance_after":6971772,"source":{"system":"sec-edgar","filing":"0001104659-20-081337","document":"tm2024196-2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/14272/000110465920081337/tm2024196-2_4.xml","form_type":"4"}},{"id":3372072,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153826,"kind":"organization","name":"Celgene European Investment Co LLC","position":2,"cik":"0001577650","reported_name":"Celgene European Investment Co LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153827,"kind":"organization","name":"Celgene Switzerland LLC","position":3,"cik":"0001661486","reported_name":"Celgene Switzerland LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153828,"kind":"organization","name":"Celgene Alpine Investment Co., LLC","position":4,"cik":"0001581774","reported_name":"Celgene Alpine Investment Co., LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-11-14T16:06:15.000Z","date":"2019-11-12","kind":"purchase","acquired":true,"shares":403225,"price":31,"value":12499975.0,"ownership":{"direct":true},"balance_after":1777824,"source":{"system":"sec-edgar","filing":"0001104659-19-064171","document":"tm1922788d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000110465919064171/tm1922788d1_4.xml","form_type":"4"}},{"id":3691243,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-01-22T17:00:16.000Z","date":"2019-01-18","kind":"purchase","acquired":true,"shares":706206,"price":43,"value":30366858.0,"ownership":{"direct":true},"balance_after":6824685,"source":{"system":"sec-edgar","filing":"0001415889-19-000088","document":"form4-01222019_050101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919000088/form4-01222019_050101.xml","form_type":"4"}},{"id":3803262,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Redeemable Convertible Preferred Stock","published_at":"2018-10-02T16:10:40.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":18726075,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Upon closing of the Issuer's initial public offering, each share of Series E redeemable convertible preferred stock automatically converted into 0.0275 share of Common Stock without payment of further consideration. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon closing of the Issuer's initial public offering, each share of Series E redeemable convertible preferred stock automatically converted into 0.0275 share of Common Stock without payment of further consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Upon closing of the Issuer's initial public offering, each share of Series E redeemable convertible preferred stock automatically converted into 0.0275 share of Common Stock without payment of further consideration. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":514967},"source":{"system":"sec-edgar","filing":"0001415889-18-001458","document":"form4-10022018_011020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588918001458/form4-10022018_011020.xml","form_type":"4"}},{"id":3803261,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D-2 Redeemable Convertible Preferred Stock","published_at":"2018-10-02T16:10:40.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":18097331,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series D-2 redeemable convertible preferred stock automatically converted into 0.0419 share of Common Stock without payment of further consideration. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series D-2 redeemable convertible preferred stock automatically converted into 0.0419 share of Common Stock without payment of further consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series D-2 redeemable convertible preferred stock automatically converted into 0.0419 share of Common Stock without payment of further consideration. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":758278},"source":{"system":"sec-edgar","filing":"0001415889-18-001458","document":"form4-10022018_011020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588918001458/form4-10022018_011020.xml","form_type":"4"}},{"id":3803260,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Redeemable Convertible Preferred Stock","published_at":"2018-10-02T16:10:40.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":2845114,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Upon closing of the Issuer's initial public offering, each share of Series D redeemable convertible preferred stock automatically converted into 0.0405 share of Common Stock without payment of further consideration. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon closing of the Issuer's initial public offering, each share of Series D redeemable convertible preferred stock automatically converted into 0.0405 share of Common Stock without payment of further consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Upon closing of the Issuer's initial public offering, each share of Series D redeemable convertible preferred stock automatically converted into 0.0405 share of Common Stock without payment of further consideration. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":115227},"source":{"system":"sec-edgar","filing":"0001415889-18-001458","document":"form4-10022018_011020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588918001458/form4-10022018_011020.xml","form_type":"4"}},{"id":3803259,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Redeemable Convertible Preferred Stock","published_at":"2018-10-02T16:10:40.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":8338892,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series C-2 redeemable convertible preferred stock automatically converted into 0.0405 share of Common Stock without payment of further consideration. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series C-2 redeemable convertible preferred stock automatically converted into 0.0405 share of Common Stock without payment of further consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series C-2 redeemable convertible preferred stock automatically converted into 0.0405 share of Common Stock without payment of further consideration. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":337725},"source":{"system":"sec-edgar","filing":"0001415889-18-001458","document":"form4-10022018_011020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588918001458/form4-10022018_011020.xml","form_type":"4"}},{"id":3803258,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T16:10:40.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":1726197,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series C-2 redeemable convertible preferred stock automatically converted into 0.0405 share of Common Stock without payment of further consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon closing of the Issuer's initial public offering, each share of Series D redeemable convertible preferred stock automatically converted into 0.0405 share of Common Stock without payment of further consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon closing of the Issuer's initial public offering, each share of Series D-2 redeemable convertible preferred stock automatically converted into 0.0419 share of Common Stock without payment of further consideration. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon closing of the Issuer's initial public offering, each share of Series E redeemable convertible preferred stock automatically converted into 0.0275 share of Common Stock without payment of further consideration. The shares had no expiration date."}],"balance_after":1726197,"source":{"system":"sec-edgar","filing":"0001415889-18-001458","document":"form4-10022018_011020.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588918001458/form4-10022018_011020.xml","form_type":"4"}},{"id":4084023,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153827,"kind":"organization","name":"Celgene Switzerland LLC","position":2,"cik":"0001661486","reported_name":"Celgene Switzerland LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153828,"kind":"organization","name":"Celgene Alpine Investment Co., LLC","position":3,"cik":"0001581774","reported_name":"Celgene Alpine Investment Co., LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153826,"kind":"organization","name":"Celgene European Investment Co LLC","position":4,"cik":"0001577650","reported_name":"Celgene European Investment Co LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-01-31T08:39:40.000Z","date":"2018-01-23","kind":"purchase","acquired":true,"shares":851154,"price":67,"value":57027318.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This Form 4 Amendment is being submitted to correct the date of earliest transaction in box 3 to reflect January 23, 2018."}],"balance_after":1374599,"source":{"system":"sec-edgar","filing":"0001209191-18-006131","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919118006131/doc4a.xml","form_type":"4/A","original_submission_date":"2018-01-23"}},{"id":4092965,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153827,"kind":"organization","name":"Celgene Switzerland LLC","position":2,"cik":"0001661486","reported_name":"Celgene Switzerland LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153828,"kind":"organization","name":"Celgene Alpine Investment Co., LLC","position":3,"cik":"0001581774","reported_name":"Celgene Alpine Investment Co., LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153826,"kind":"organization","name":"Celgene European Investment Co LLC","position":4,"cik":"0001577650","reported_name":"Celgene European Investment Co LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-01-23T16:35:54.000Z","date":"2018-01-23","kind":"purchase","acquired":true,"shares":851154,"price":67,"value":57027318.0,"ownership":{"direct":true},"balance_after":1374599,"source":{"system":"sec-edgar","filing":"0001209191-18-004895","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919118004895/doc4.xml","form_type":"4"}},{"id":4139721,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-07T09:57:51.000Z","date":"2017-12-04","kind":"sale","acquired":false,"shares":30485,"price":19.47,"value":593542.95,"ownership":{"direct":false,"nature":"See explanation of responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":3722534,"source":{"system":"sec-edgar","filing":"0001209191-17-064325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117064325/doc4.xml","form_type":"4"}},{"id":4139720,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-07T09:57:51.000Z","date":"2017-12-01","kind":"sale","acquired":false,"shares":87991,"price":19.1,"value":1680628.1,"ownership":{"direct":false,"nature":"See explanation of responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":3753019,"source":{"system":"sec-edgar","filing":"0001209191-17-064325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117064325/doc4.xml","form_type":"4"}},{"id":4139719,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-07T09:57:51.000Z","date":"2017-11-30","kind":"sale","acquired":false,"shares":12666,"price":19.04,"value":241160.64,"ownership":{"direct":false,"nature":"See explanation of responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":3841010,"source":{"system":"sec-edgar","filing":"0001209191-17-064325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117064325/doc4.xml","form_type":"4"}},{"id":4139718,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-07T09:57:51.000Z","date":"2017-11-29","kind":"sale","acquired":false,"shares":4263,"price":19.25,"value":82062.75,"ownership":{"direct":false,"nature":"See explanation of responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":3853676,"source":{"system":"sec-edgar","filing":"0001209191-17-064325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117064325/doc4.xml","form_type":"4"}},{"id":4139717,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-07T09:57:51.000Z","date":"2017-11-28","kind":"sale","acquired":false,"shares":5080,"price":19.22,"value":97637.6,"ownership":{"direct":false,"nature":"See explanation of responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":3857939,"source":{"system":"sec-edgar","filing":"0001209191-17-064325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117064325/doc4.xml","form_type":"4"}},{"id":4139716,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-07T09:57:51.000Z","date":"2017-11-27","kind":"sale","acquired":false,"shares":27990,"price":19.75,"value":552802.5,"ownership":{"direct":false,"nature":"See explanation of responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":3863019,"source":{"system":"sec-edgar","filing":"0001209191-17-064325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117064325/doc4.xml","form_type":"4"}},{"id":4139715,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-07T09:57:51.000Z","date":"2017-11-24","kind":"sale","acquired":false,"shares":26010,"price":20,"value":520200.0,"ownership":{"direct":false,"nature":"See explanation of responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":3891009,"source":{"system":"sec-edgar","filing":"0001209191-17-064325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117064325/doc4.xml","form_type":"4"}},{"id":4139714,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-07T09:57:51.000Z","date":"2017-11-22","kind":"sale","acquired":false,"shares":256000,"price":19.76,"value":5058560.0,"ownership":{"direct":false,"nature":"See explanation of responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":3917019,"source":{"system":"sec-edgar","filing":"0001209191-17-064325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117064325/doc4.xml","form_type":"4"}},{"id":4139713,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-07T09:57:51.000Z","date":"2018-11-21","kind":"sale","acquired":false,"shares":80000,"price":19.25,"value":1540000.0,"ownership":{"direct":false,"nature":"See explanation of responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":4173019,"source":{"system":"sec-edgar","filing":"0001209191-17-064325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117064325/doc4.xml","form_type":"4"}},{"id":4139712,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-07T09:57:51.000Z","date":"2017-11-20","kind":"sale","acquired":false,"shares":158718,"price":19.02,"value":3018816.36,"ownership":{"direct":false,"nature":"See explanation of responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":4253019,"source":{"system":"sec-edgar","filing":"0001209191-17-064325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117064325/doc4.xml","form_type":"4"}},{"id":4139711,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-07T09:57:51.000Z","date":"2017-11-17","kind":"sale","acquired":false,"shares":51282,"price":18.44,"value":945640.08,"ownership":{"direct":false,"nature":"See explanation of responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":4411737,"source":{"system":"sec-edgar","filing":"0001209191-17-064325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117064325/doc4.xml","form_type":"4"}},{"id":4139710,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-07T09:57:51.000Z","date":"2017-11-16","kind":"sale","acquired":false,"shares":105000,"price":18.39,"value":1930950.0,"ownership":{"direct":false,"nature":"See explanation of responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":4463019,"source":{"system":"sec-edgar","filing":"0001209191-17-064325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117064325/doc4.xml","form_type":"4"}},{"id":4139709,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-07T09:57:51.000Z","date":"2017-11-15","kind":"sale","acquired":false,"shares":15000,"price":17.67,"value":265050.0,"ownership":{"direct":false,"nature":"See explanation of responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":4568019,"source":{"system":"sec-edgar","filing":"0001209191-17-064325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117064325/doc4.xml","form_type":"4"}},{"id":4139708,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-07T09:57:51.000Z","date":"2017-11-14","kind":"sale","acquired":false,"shares":14907,"price":17.19,"value":256251.33,"ownership":{"direct":false,"nature":"See explanation of responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":4583019,"source":{"system":"sec-edgar","filing":"0001209191-17-064325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117064325/doc4.xml","form_type":"4"}},{"id":4139707,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-07T09:57:51.000Z","date":"2017-11-13","kind":"sale","acquired":false,"shares":65093,"price":17.76,"value":1156051.68,"ownership":{"direct":false,"nature":"See explanation of responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":4597926,"source":{"system":"sec-edgar","filing":"0001209191-17-064325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117064325/doc4.xml","form_type":"4"}},{"id":4139706,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-07T09:57:51.000Z","date":"2017-11-10","kind":"sale","acquired":false,"shares":10000,"price":17.28,"value":172800.0,"ownership":{"direct":false,"nature":"See explanation of responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":4663019,"source":{"system":"sec-edgar","filing":"0001209191-17-064325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117064325/doc4.xml","form_type":"4"}},{"id":4139705,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-07T09:57:51.000Z","date":"2017-11-09","kind":"sale","acquired":false,"shares":20000,"price":17.08,"value":341600.0,"ownership":{"direct":false,"nature":"See explanation of responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":4673019,"source":{"system":"sec-edgar","filing":"0001209191-17-064325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117064325/doc4.xml","form_type":"4"}},{"id":4139704,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-07T09:57:51.000Z","date":"2017-11-08","kind":"sale","acquired":false,"shares":16875,"price":18.06,"value":304762.5,"ownership":{"direct":false,"nature":"See explanation of responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":4693019,"source":{"system":"sec-edgar","filing":"0001209191-17-064325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117064325/doc4.xml","form_type":"4"}},{"id":4139703,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-07T09:57:51.000Z","date":"2017-11-07","kind":"sale","acquired":false,"shares":23000,"price":18.54,"value":426420.0,"ownership":{"direct":false,"nature":"See explanation of responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":4709894,"source":{"system":"sec-edgar","filing":"0001209191-17-064325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117064325/doc4.xml","form_type":"4"}},{"id":4139702,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-07T09:57:51.000Z","date":"2017-11-06","kind":"sale","acquired":false,"shares":79327,"price":18.89,"value":1498487.03,"ownership":{"direct":false,"nature":"See explanation of responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":4732894,"source":{"system":"sec-edgar","filing":"0001209191-17-064325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117064325/doc4.xml","form_type":"4"}},{"id":4139701,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-07T09:57:51.000Z","date":"2017-11-03","kind":"sale","acquired":false,"shares":22759,"price":19.1,"value":434696.9,"ownership":{"direct":false,"nature":"See explanation of responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":4812221,"source":{"system":"sec-edgar","filing":"0001209191-17-064325","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117064325/doc4.xml","form_type":"4"}},{"id":4202785,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-09-25T16:23:53.000Z","date":"2017-09-25","kind":"purchase","acquired":true,"shares":745592,"price":37,"value":27586904.0,"ownership":{"direct":true},"balance_after":6118479,"source":{"system":"sec-edgar","filing":"0001209191-17-053822","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117053822/doc4.xml","form_type":"4"}},{"id":4347043,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":153826,"kind":"organization","name":"Celgene European Investment Co LLC","position":1,"cik":"0001577650","reported_name":"Celgene European Investment Co LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153827,"kind":"organization","name":"Celgene Switzerland LLC","position":2,"cik":"0001661486","reported_name":"Celgene Switzerland LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153828,"kind":"organization","name":"Celgene Alpine Investment Co., LLC","position":3,"cik":"0001581774","reported_name":"Celgene Alpine Investment Co., LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":4,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-04-24T16:34:16.000Z","date":"2017-04-24","kind":"purchase","acquired":true,"shares":624575,"price":49.5,"value":30916462.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Of these shares, 624,575 shares are owned directly by Celgene Switzerland LLC (\"Celgene Switzerland\"), 708,333 shares are owned directly by Celgene Alpine Investment Co. LLC (\"Celgene Alpine\"), each a wholly-owned subsidiary of Celgene Corporation (\"Celgene\"), and Celgene has the power to vote, acquire, hold and dispose of all such shares.  Celgene and Celgene European Investment Company LLC, a wholly owned subsidiary of Celgene (\"CEICO\"), disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.  The remaining 523,445 shares are owned directly by Celgene.  CEICO, Celgene Switzerland and Celgene Alpine disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":1856353,"source":{"system":"sec-edgar","filing":"0001209191-17-027983","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117027983/doc4.xml","form_type":"4"}},{"id":4353008,"issuer":{"id":155807,"kind":"organization","name":"Adynxx, Inc.","symbol":"ADYX"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-04-13T16:07:05.000Z","date":"2017-04-11","kind":"other","acquired":true,"shares":296277,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a Securities Purchase Agreement (the \"Securities Purchase Agreement\"), dated February 27, 2017, with the Issuer, the Reporting Person purchased in a private placement (the \"Private Placement\") 4,000,000 shares of Common Stock at a purchase price of $0.50 per share (the \"Per Share Purchase Price\"). The Securities Purchase Agreement contains a \"most-favored nation\" provision that provides that if the Issuer, during 120 days from February 27, 2017, issues or sells any Common Stock or Common Stock equivalents reasonably believed to be more favorable in terms or conditions than the Private Placement, the Issuer must amend the terms of the Securities Purchase Agreement to give the Private Placement investors, including the Reporting Person, the benefit of such more favorable terms or conditions."},{"field":"kind","element":"transactionCoding","label":"F2","text":"In accordance with this provision, effective as of April 11, 2017, following a public offering of Common Stock at a purchase price of $0.40 per share (the \"Public Offering Price\") on April 3, 2017, the Issuer adjusted the Per Share Purchase Price to the Public Offering Price, and is required to issue additional shares of Common Stock to the Private Placement investors, including the Reporting Person, which issuance is subject to stockholder approval as may be required by the applicable rules and regulations of the NASDAQ Capital Market and certain side letter agreement, dated March 13, 2017, between the Issuer and the Reporting Person (the \"Side Letter\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Securities Purchase Agreement and subject to the Side Letter, on April 11, 2017, the Issuer issued 296,277 shares of Common Stock to the Reporting Person (the \"MFN Shares\"), and will issue 703,723 additional shares of Common Stock to the Reporting Person if the Issuer obtains stockholder approval as may be required by the applicable rules and regulations of the NASDAQ Capital Market."}],"balance_after":7342377,"source":{"system":"sec-edgar","filing":"0001209191-17-026849","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117026849/doc4.xml","form_type":"4"}},{"id":4415820,"issuer":{"id":155807,"kind":"organization","name":"Adynxx, Inc.","symbol":"ADYX"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-03-01T16:19:10.000Z","date":"2017-02-27","kind":"purchase","acquired":true,"shares":4000000,"price":0.5,"value":2000000.0,"ownership":{"direct":true},"balance_after":7046100,"source":{"system":"sec-edgar","filing":"0001209191-17-015840","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117015840/doc4.xml","form_type":"4"}},{"id":4474307,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":153827,"kind":"organization","name":"Celgene Switzerland LLC","position":1,"cik":"0001661486","reported_name":"Celgene Switzerland LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":2,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2017-02-01T16:18:28.000Z","date":"2017-02-01","kind":"exercise","acquired":false,"shares":10448100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B-1 Preferred Stock automatically converted into 0.271 share of Common Stock without payment of further consideration. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B-1 Preferred Stock automatically converted into 0.271 share of Common Stock without payment of further consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B-1 Preferred Stock automatically converted into 0.271 share of Common Stock without payment of further consideration. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation (\"Celgene\"), and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2831463},"source":{"system":"sec-edgar","filing":"0001209191-17-006676","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117006676/doc4.xml","form_type":"4"}},{"id":4474306,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":153827,"kind":"organization","name":"Celgene Switzerland LLC","position":1,"cik":"0001661486","reported_name":"Celgene Switzerland LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":2,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-02-01T16:18:28.000Z","date":"2017-02-01","kind":"purchase","acquired":true,"shares":625000,"price":16,"value":10000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation (\"Celgene\"), and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":3456463,"source":{"system":"sec-edgar","filing":"0001209191-17-006676","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117006676/doc4.xml","form_type":"4"}},{"id":4474305,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":153827,"kind":"organization","name":"Celgene Switzerland LLC","position":1,"cik":"0001661486","reported_name":"Celgene Switzerland LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":2,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-02-01T16:18:28.000Z","date":"2017-02-01","kind":"exercise","acquired":true,"shares":2831463,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B-1 Preferred Stock automatically converted into 0.271 share of Common Stock without payment of further consideration. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation (\"Celgene\"), and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":2831463,"source":{"system":"sec-edgar","filing":"0001209191-17-006676","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117006676/doc4.xml","form_type":"4"}},{"id":4573704,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Shares","published_at":"2016-10-27T16:45:41.000Z","date":"2016-10-24","kind":"exercise","acquired":false,"shares":4034830,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Explanation of Responses"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These securities converted on a one-for-one basis into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities converted on a one-for-one basis into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"These securities were convertible at any time on a one-for-one basis into shares of the Issuer's Common Stock at the holder's election and automatically upon the closing of the Issuer's initial public offering. These securities do not have an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":0,"exercise_date":"2016-10-24","underlying":"Common Shares","underlying_shares":4034830},"source":{"system":"sec-edgar","filing":"0001209191-16-147161","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919116147161/doc4a.xml","form_type":"4/A","original_submission_date":"2016-10-26"}},{"id":4573703,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-10-27T16:45:41.000Z","date":"2016-10-24","kind":"purchase","acquired":true,"shares":800150,"price":14,"value":11202100.0,"ownership":{"direct":false,"nature":"See Explanation of Responses"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":4834980,"source":{"system":"sec-edgar","filing":"0001209191-16-147161","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919116147161/doc4a.xml","form_type":"4/A","original_submission_date":"2016-10-26"}},{"id":4573702,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-10-27T16:45:41.000Z","date":"2016-10-24","kind":"exercise","acquired":true,"shares":4034830,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Explanation of Responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities converted on a one-for-one basis into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":4034830,"source":{"system":"sec-edgar","filing":"0001209191-16-147161","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919116147161/doc4a.xml","form_type":"4/A","original_submission_date":"2016-10-26"}},{"id":4574350,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Shares","published_at":"2016-10-26T16:15:45.000Z","date":"2016-10-24","kind":"exercise","acquired":false,"shares":4034830,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These securities converted on a one-for-one basis into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities converted on a one-for-one basis into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"These securities were convertible at any time on a one-for-one basis into shares of the Issuer's Common Stock at the holder's election and automatically upon the closing of the Issuer's initial public offering. These securities do not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":0,"exercise_date":"2016-10-24","underlying":"Common Shares","underlying_shares":4034830},"source":{"system":"sec-edgar","filing":"0001209191-16-146978","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919116146978/doc4.xml","form_type":"4"}},{"id":4574349,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-10-26T16:15:45.000Z","date":"2016-10-24","kind":"purchase","acquired":true,"shares":800150,"price":14,"value":11202100.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":4834980,"source":{"system":"sec-edgar","filing":"0001209191-16-146978","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919116146978/doc4.xml","form_type":"4"}},{"id":4574348,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-10-26T16:15:45.000Z","date":"2016-10-24","kind":"exercise","acquired":true,"shares":4034830,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities converted on a one-for-one basis into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation (\"Celgene\"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose."}],"balance_after":4034830,"source":{"system":"sec-edgar","filing":"0001209191-16-146978","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919116146978/doc4.xml","form_type":"4"}}]}